SangHyun Kang - INtRON Biotechnology CTO Department
| 048530 Stock | KRW 5,440 110.00 1.98% |
Insider
SangHyun Kang is CTO Department of iNtRON Biotechnology
| Age | 55 |
| Phone | 82 3 1739 5678 |
| Web | https://www.intron.co.kr |
INtRON Biotechnology Management Efficiency
The company has return on total asset (ROA) of 0.0519 % which means that it generated a profit of $0.0519 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 11.1617 %, meaning that it generated $11.1617 on every $100 dollars invested by stockholders. INtRON Biotechnology's management efficiency ratios could be used to measure how well INtRON Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hwan Sung | AptaBio Therapeutics | N/A | |
| Jong Won | ABL Bio | N/A | |
| You WeonKyoo | ABL Bio | N/A | |
| Jung Kim | ABL Bio | N/A | |
| Jae Jung | ABL Bio | N/A | |
| Sang Lee | ABL Bio | N/A | |
| Sang Joo | SillaJen | 54 | |
| Cheol Park | SillaJen | 52 | |
| Hyeok Gwon | SillaJen | 51 | |
| Jong Kim | ABL Bio | N/A | |
| Changman Chae | Woori Technology Investment | N/A | |
| Junghoon Lee | Woori Technology Investment | 46 | |
| Seungdo Lee | Woori Technology Investment | 58 | |
| Byeong Kim | SillaJen | 51 | |
| Jeong Noh | SillaJen | 66 | |
| Seong Chi | SillaJen | 67 | |
| Hyeon Shin | SillaJen | 47 | |
| Jong Park | SillaJen | 58 | |
| Gyeong Ha | SillaJen | 45 | |
| Gyeong Hwang | SillaJen | 42 | |
| YeongGuk Cho | Woori Technology Investment | N/A | |
Management Performance
| Return On Equity | 11.16 | |||
| Return On Asset | 0.0519 |
iNtRON Biotechnology Leadership Team
Elected by the shareholders, the INtRON Biotechnology's board of directors comprises two types of representatives: INtRON Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of INtRON. The board's role is to monitor INtRON Biotechnology's management team and ensure that shareholders' interests are well served. INtRON Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, INtRON Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SangHyun Kang, CTO Department | ||
| Kyung Yoon, Chief Management | ||
| Ji Park, Executive Director of Production | ||
| SeongJun Yoon, Chief Pres | ||
| JaeKoo Seol, MD Department | ||
| Soo Jun, Director RD |
INtRON Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is INtRON Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 11.16 | |||
| Return On Asset | 0.0519 | |||
| Profit Margin | 0.34 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 734.71 B | |||
| Shares Outstanding | 29.88 M | |||
| Shares Owned By Insiders | 15.72 % | |||
| Shares Owned By Institutions | 8.10 % | |||
| Price To Earning | 313.17 X | |||
| Price To Sales | 9.32 X |
Pair Trading with INtRON Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INtRON Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INtRON Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with INtRON Stock
Moving against INtRON Stock
The ability to find closely correlated positions to INtRON Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INtRON Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INtRON Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iNtRON Biotechnology to buy it.
The correlation of INtRON Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INtRON Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iNtRON Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INtRON Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in INtRON Stock
INtRON Biotechnology financial ratios help investors to determine whether INtRON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in INtRON with respect to the benefits of owning INtRON Biotechnology security.